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Original article
The pairing of the average of blood pressure (BP) measure-
ments derived from out-of-office BP monitoring with office 
BP measurements yields 4 possible diagnostic categories 
(Figure  1). White-coat hypertension refers to the scenario 
of elevated office BP with nonelevated out-of-office average. 
Based on cost-savings from not treating such patients, clini-
cal guidelines recently developed by the National Institute 
for Healthcare and Clinical Excellence in the United 
Kingdom recommend ambulatory BP monitoring (ABPM) 
for patients with elevated office BP to confirm hypertension 
before initiating drug treatment.1,2
What is not considered in the National Institute for 
Healthcare and Clinical Excellence guidelines and most 
other guidelines, however, is that approximately 10% 
of the general population, and a high proportion of 
clinic patients, has masked hypertension (MH).3,4 MH 
is defined as nonelevated office BP with elevated average 
out-of-office BP, and it conveys cardiovascular disease 
(CVD) risk approaching that associated with sustained 
hypertension.5–8
In current US practice, an initially elevated BP in the office 
(which can be considered a positive screening measure-
ment) calls for follow-up office BP measurements to confirm 
or refute the presence of hypertension.9 The follow-up office 
measurements could be considered the diagnostic measure-
ments, and there is generally no further discerning diagnos-
tic testing performed. Additionally, in current practice, a 
nonelevated office BP would not be an indication for further 
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background
Masked hypertension (MH)—nonelevated office blood pressure (BP) 
with elevated out-of-office BP average—conveys cardiovascular risk 
similar to or approaching sustained hypertension, making its detec-
tion of potential clinical importance. However, it may not be feasible 
or cost-effective to perform ambulatory BP monitoring (ABPM) on 
all patients with a nonelevated office BP. There likely exists a level of 
office BP below which ABPM is not warranted because the probability 
of MH is low.
methods
We analyzed data from 294 adults aged ≥30  years not on 
BP-lowering medication with office BP <140/90 mm Hg, all of whom 
underwent 24-hour ABPM. We calculated sensitivity, false-positive 
rate, and likelihood ratios (LRs) for the range of office BP cutoffs 
from 110 to 138 mm Hg systolic and from 68 to 88 mm Hg diastolic 
for detecting MH.
results
The systolic BP cutoff with the highest +LR for detecting MH (1.8) was 
120 mm Hg, and the diastolic cutoff with the highest +LR (2.4) was 82 mm 
Hg. However, the systolic level of 120 mm Hg had a false-positive rate of 
42%, and the diastolic level of 82 mm Hg had a sensitivity of only 39%.
conclusions
The cutoff of office BP with the best overall operating characteristics for 
diagnosing MH is approximately 120/82 mm Hg. However, this cutoff 
may have an unacceptably high false-positive rate. Clinical risk tools to 
identify patients with nonelevated office BP for whom ABPM should be 
considered will likely need to include factors in addition to office BP.
Keywords: ambulatory blood pressure monitoring; blood pressure; 
diagnosis; hypertension; masked hypertension; screening.
doi:10.1093/ajh/hpu099
Correspondence: Anthony J. Viera (anthony_viera@med.unc.edu).
Initially submitted January 7, 2014; date of first revision February 26, 
2014; accepted for publication April 26, 2014; online publication June 
4, 2014.
© American Journal of Hypertension, Ltd 2014. All rights reserved. 
For Permissions, please email: journals.permissions@oup.com
1Department of Family Medicine, University of North Carolina School of 
Medicine, Chapel Hill, North Carolina;  2Hypertension Research Program, 
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina;  
3Department of Biostatistics, Gillings School of Global Public Health, 
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina;  
4Department of Medicine, Center for Behavioral Cardiovascular Health, 
Columbia University Medical Center, New York, New York;  5Department 
of Medicine, Division of Cardiology, University of North Carolina School 
of Medicine, Chapel Hill, North Carolina. 
January
2015
American Journal of Hypertension 28(1) January 2015 43
Office BP Cutoffs for Detecting Masked Hypertension
testing outside of routine office screening at periodic health 
checkups. Unfortunately, this approach leads to misclassifi-
cation (i.e., misdiagnosis) of many people when compared 
with measurements obtained from ABPM, which provides 
the best assessment of someone’s true BP status.10 Patients 
with an elevated office BP may have normal ambulatory BP 
(a false-positive office screen), and patients with a normal 
office BP may have elevated ambulatory BP (a false-negative 
office screen).
It likely would not be feasible or cost-effective to per-
form ABPM on all patients with nonelevated office BP 
(to rule out MH) in addition to the suggested strategy of 
performing ABPM on all patients with elevated office BP 
(to rule out white-coat hypertension).2 Therefore, it would 
be valuable to have a strategy to guide clinical decision-
making about which patients with nonelevated office BP 
ought to have ABPM. Previous studies have shown that 
MH is more likely among patients with office prehyper-
tension, particularly in the upper (borderline) range (e.g., 
130–139/85–89 mm Hg).4,11 An approach that uses screen-
ing office BP level to guide ABPM testing decisions for 
persons with nonelevated office BP should be considered. 
There is likely a BP level below which very few people have 
MH. Using diagnostic out-of-office measurements (e.g., 
ABPM) for people with a BP above such a level may enable 
those with MH to be identified while minimizing excess 
testing. The goal of this analysis is to begin to define the 
office BP level above which ABPM should be considered 
for detecting MH.
METHODS
Study recruitment and setting
For a larger BP measurement study, we recruited 420 
primary care patients aged ≥30  years with no diagnosis of 
hypertension and not taking any BP-lowering medications. 
The most recent BP measured in the outpatient clinic had to 
be between 120 and 149 mm Hg systolic or 80 and 95 mm 
Hg diastolic and not >149/95 mm Hg. Exclusion criteria 
included pregnancy, dementia, any condition that would 
preclude wearing an ambulatory BP monitor, and persis-
tent atrial fibrillation or other arrhythmia. We also excluded 
potential enrollees if the initial office BP at the research visit 
was ≥160/100 mm Hg. All study procedures took place in a 
clinical research center. For this analysis, only the 294 partici-
pants with a research visit office BP average <140/90 mm Hg 
were included.
Office BP
After check-in procedures at the study visit, partici-
pants were placed in an exam room in the clinical research 
center. After at least a 5-minute rest, same-arm BP was 
measured 3 times with the subject appropriately prepared 
and positioned9 using a validated office-type oscillometric 
device (Welch Allyn Vital Signs Welch Allyn, Skaneateles 
Falls, NY)12 equipped with an appropriately sized cuff. The 
second and third measurements were averaged to deter-
mine the participant’s office BP for the visit.
Ambulatory BP monitoring
At the conclusion of the study visit, participants were fit-
ted with an Oscar 2 oscillometric monitor (Suntech Medical, 
Morrisville, NC) with an appropriately sized cuff for 
24-hour ambulatory BP monitoring. The Oscar 2 has been 
validated for use in adults by both the British Hypertension 
Society protocol and the International Protocol for the 
validation of BP measuring devices.13,14 The monitors were 
programmed to measure BP at 30-minute intervals from 
6 am to 10 pm and at 1-hour intervals from 10 pm to 6 
am. We chose these intervals rather than more frequent 
intervals to minimize participant burden. For most partici-
pants, we used a diary to define sleep and awake periods. 
For those missing a diary (n  =  95), we defined awake as 
10 am to 10 pm and the sleep period as midnight to 6 am. 
Maximum BP measurement time was limited to <140 sec-
onds, and the monitors were set for a maximum pressure 
of 220 mm Hg. Participants were encouraged to leave the 
cuff on during the entire monitoring period and to hold 
their cuffed arm as still as possible during cuff inflation and 
deflation to ensure that the monitor would acquire an accu-
rate reading and were informed that faulty readings would 
trigger a repeat measurement. A minimum of 14 awake and 
6 sleep readings were required for an ABPM session to be 
considered adequate.15
Additional variables
We collected demographic information, including age, 
self-reported race, education level, and insurance status. 
We asked participants to rate their health using a standard 
question with answers ranging from poor to excellent.16 
We measured height and weight and calculated body mass 
index.
Office BP average 
≥140/90 mm Hg <140/90 mm Hg 
≥135/85* mm Hg Sustained hypertension Masked hypertension Out-of-office  
BP average <135/85* mm Hg White-coat hypertension Sustained normotension 
Note that classification is based on either systolic, diastolic, or both 
                                *<130/80 mm Hg if sleep measurements from 24-hour ambulatory BP data included 
Figure 1. Categories of blood pressure (BP) based on pairing office and out-of-office measurements. Note that classification is based on either systolic, 
diastolic, or both. The asterisk (*) indicates that <130/80 mm Hg was used if sleep measurements form 24-hour ambulatory BP data were included.
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Analysis
We used the research visit office BP measurements and 
the corresponding 24-hour ABPM session to calculate the 
prevalence of MH among the study participants. We defined 
MH as office BP average <140/90 mm Hg with 24-hour 
ABPM average ≥130 mm Hg systolic or ≥80 mm Hg dias-
tolic. We then calculated sensitivity and specificity for lev-
els of office systolic BP from 110 mm Hg to 138 mm Hg and 
diastolic BP from 68 mm Hg to 88 mm Hg for diagnosing 
MH. From these data, we report sensitivity, false-positive 
rate (1 − specificity), positive likelihood ratio, and negative 
likelihood ratio. Sensitivity represents the proportion of peo-
ple with MH who would be detected. Specificity represents 
the proportion of people without MH who would be classi-
fied as such; therefore 1 − specificity (i.e., false-positive rate) 
represents the proportion of people with normal ambulatory 
BP who would screen positive (and be tested unnecessarily). 
A  likelihood ratio represents how many times more likely 
the screening result would be found in those with the out-
come than without it. A likelihood ratio of 1 means the test 
is not helpful at all, in this case in distinguishing people who 
did and did not have MH.
We also present the receiver operator characteristic curves 
for both systolic and diastolic office BP measurements for 
detecting MH. Receiver operator characteristic curves plot 
the sensitivity against the false-positive rate across all lev-
els of the screening test (in this case the office BP levels). 
We also created a scatterplot depicting the cutoff for which 
the optimal classification is reached based on the maximum 
positive likelihood ratio in systolic and diastolic office BP.
Study approval
This study was approved by the Office of Human Research 
Ethics at the University of North Carolina at Chapel Hill.
RESULTS
Participant characteristics
The mean ± SD age of the study sample participants was 
47 ± 12 years. Most participants were aged 30–44 years (46%) 
or 45–64 years (43%) (Table 1). A small proportion was aged 
≥65  years (11%). Approximately 22% were black. Nearly 
three-fourths were college graduates (74%), and nearly all 
(94%) reported good to excellent health. Most were over-
weight (30%) or obese (41%) and nonsmokers (92%). The 
majority were married or living with a partner. Most partici-
pants (72%) had >20 awake ambulatory BP measurements 
and at least 6 sleep measurements during their ABPM ses-
sion. Only 1 participant did not have sufficient awake ambu-
latory BP monitor readings.
BP and prevalence of MH
The mean ± SD office BP average of participants at the 
initial research visit was 123/78 ± 8/7 mm Hg. The overall 
prevalence of MH based on the research office BP average 
and corresponding ABPM session average was 69% (95% 
confidence interval (CI) = 64%–75%) (Table 2). Among the 
subset of participants with systolic BP of 110–119 mm Hg, 
the prevalence was 51% (95% CI = 39%–62%). The preva-
lence increased to approximately 80% among the groups 
with systolic BP of 120–129 mm Hg and 130–139 mm Hg. 
A similar pattern was seen when participants were stratified 
by diastolic BP levels.
Sensitivity and specificity of systolic BP cutoffs
The sensitivity and false-positive rates (1 – specificity) for 
detecting MH in the study sample based on increasing lev-
els of office systolic BP cutoffs from 110 mm Hg to 138 mm 
Table 1. Participant characteristics (n = 294)
Characteristic No. %
Age group, y
 30–44 135 46
 45–64 127 43
 >65 32 11
Female sex 178 61
Race
 Black 66 22
 White 217 74
 Other 11 4
Hispanic ethnicity 14 5
Education level
 Some high school 5 2
 High school graduate 16 5
 Some college 56 19
 College graduate 127 74
Insurance status
 Private 207 71
 Public 38 13
 Both 29 10
 Uninsured 18 6
Self-reported health
 Excellent/very good 109 68
 Good 77 26
 Fair or poor 18 6
Nonsmoker 271 92
Drink alcohol 200 68
BMI
 Normal (<25 kg/m2) 86 29
 Overweight (25–29 kg/m2) 88 30
 Obese (≥30 kg/m2) 120 41
Married or living with partner 183 62
Abbreviation: BMI, body mass index.
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Hgmm are shown in Table 3 and depicted in Figure 2. Above 
the lowest included cutoff of 110 mm Hg, 97% of partici-
pants with MH would be detected, but the false-positive 
rate would be 87%. At the highest included cutoff of 138 mm 
Hg, there are very few false positives (1%), but the sensitiv-
ity drops to <1%. The cutoff of 120 mm Hg has a sensitivity 
of 76% with a false positive rate of 42%, yielding a positive 
likelihood ratio of 1.79.
Sensitivity and specificity of diastolic BP cutoffs
The sensitivity and false-positive rates (1 – specificity) for 
detecting MH in the study sample based on increasing levels 
of office diastolic BP cutoffs from 68 mm Hg to 88 mm Hg 
are shown in Table 4 and depicted in Figure 2. At the lowest 
included cutoff of 68 mm Hg, 95% of participants with MH 
would be detected, but the false-positive rate would be 82%. 
At the highest included cutoff of 88 mm Hg, there are very 
few false positives (1%), but the sensitivity is also very low 
(3%). A  cutoff of 82 mm Hg has a sensitivity of 39% with 
a false positive rate of about 17%. The cutoff of 82 mm Hg 
yielded the best positive likelihood ratio based on a sensitiv-
ity of 39% and false-positive rate of 17%.
Maximum positive likelihood ratio
As shown in Figure 3, the maximum positive likelihood 
ratio for an office systolic BP cutoff to detect MH is approxi-
mately 120 mm Hg. The maximum positive likelihood ratio 
for an office diastolic BP cutoff to detect MH is approximately 
82 mm Hg. Using a cutoff that defines a positive screen as 
either a systolic BP >120 mm Hg or a diastolic BP >82 mm 
Hg, the sensitivity is 78% and false positive rate is 47%. The 
positive likelihood ratio is 1.68, which is slightly lower than 
the optimal positive likelihood ratio using only systolic BP.
DiSCUSSiON
Our data suggest that the office BP cutoff with the best 
operating characteristics to identify patients with MH is 
approximately 120/82 mm Hg (Tables 3 and 4; Figure  3). 
However, at this cutoff, the false-positive rate may be unac-
ceptably high. That is, many of these patients would have a 
nonelevated ambulatory BP. The amount of excess testing 
would depend on the prevalence of MH in the population. 
For example, a prevalence of 69% MH (as observed in this 
analysis) would mean that out of 100 people with a systolic 
BP <140 mm Hg, 70 would screen positive (Figure  4), but 
18 would be false positive (i.e., their ABPM average would 
not be elevated). The number of missed diagnoses also needs 
to be considered. Of the 30 who would screen negative, 17 
Table 3. Diagnostic properties of varying screening systolic office blood pressure cutoffs to diagnose masked hypertension
Office systolic blood  







110 96.6% 86.7% 1.11 0.26
112 94.6% 76.7% 1.23 0.23
114 92.2% 73.3% 1.26 0.29
116 89.2% 62.2% 1.43 0.29
118 83.8% 52.2% 1.61 0.34
120 75.5% 42.2% 1.79 0.42
122 64.7% 38.9% 1.66 0.58
124 57.4% 34.4% 1.67 0.65
126 50.0% 28.9% 1.73 0.70
128 34.8% 25.6% 1.36 0.88
130 28.9% 21.1% 1.37 0.90
132 23.0% 14.4% 1.60 0.90
134 13.7% 8.9% 1.54 0.95
136 3.9% 5.6% <1 1.02
138 0.5% 1.1% <1 1.01
Table 2. Prevalence of masked hypertension among the study 
participants (n = 294) stratified by office blood pressure average
Office blood pressure n/N (%) (95% CI)
Overall 204/294 (69) (64–75)
Systolic BP 110–119 mm Hg 39/77 (51) (39–62)
Systolic BP 120–129 mm Hg 97/118 (82) (74–88)
Systolic BP 130–139 mm Hg 63/82 (77) (66–85)
Diastolic BP 75–79 mm Hg 50/73 (68) (56–79)
Diastolic BP 80–84 mm Hg 63/76 (83) (72–90)
Diastolic BP 85–89 mm Hg 41/50 (82) (68–91)
Masked hypertension was defined as office blood pressure (BP) 
average <140/90 mm Hg with 24-hour ambulatory blood pressure 
monitoring average ≥130 mm Hg systolic or ≥80 mm Hg diastolic.
Abbreviation: CI, confidence interval.
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would actually have MH that remains undetected (false neg-
atives). If the prevalence of MH is lower, say 40%, 65 out 
of 100 would screen positive, more than half (35) of whom 
ultimately would not have MH. Of the 35 who would screen 
negative, 10 would have MH that remains undetected.
The potential clinical importance of detecting MH is evi-
dent from a number of studies demonstrating a high preva-
lence of target-organ damage in patients with this condition. 
For example, in 1 study, left ventricular mass index and 
carotid plaque among people with MH were compared with 


















































Figure 2. Receiver operator characteristic (ROC) curves for office blood pressure as a screening test for masked hypertension. (a) ROC curves for office 
systolic and diastolic blood pressure as a screening test for masked hypertension. (b) ROC curves for systolic office screening blood pressure levels. (c) 
ROC curves for diastolic office screening blood pressure levels. The dotted lines represent 95% confidence intervals.
Table 4. Diagnostic properties of varying screening diastolic office blood pressure cutoffs to diagnose masked hypertension
Office diastolic blood  







68 95.1% 82.2% 1.16 0.28
70 91.7% 68.9% 1.33 0.27
72 83.3% 60.0% 1.39 0.42
74 77.9% 53.3% 1.46 0.47
76 66.7% 43.3% 1.54 0.59
78 56.4% 28.9% 1.95 0.61
80 46.6% 24.4% 1.91 0.71
82 39.2% 16.7% 2.35 0.73
84 25.5% 13.3% 1.91 0.86
86 13.2% 6.7% 1.99 0.93
88 3.4% 1.1% 3.09a 0.98
aThis value is based on the ratio of two low percentages, so it has large variation.
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those factors among people with true normotension and 
people with sustained hypertension.5 The left ventricular 
mass index was 73 g/m2 in the true normotensives, 86 g/m2 
in the masked hypertensives, and 90 g/m2 in the sustained 
hypertensives. Carotid plaque was present in 15% of true 
normotensives and in 28% of both the masked and sustained 
hypertensives. In another study, left ventricular mass index 
in people with MH was 91 g/m2, compared with 79 g/m2 in 
true normotensives and 94 g/m2 in people with sustained 
hypertension.6 Thus, MH is associated with target-organ 
damage that is similar in magnitude to that observed in 
patients with sustained hypertension.
More important, there is also evidence of increased CVD 
events (stroke, myocardial infarction, cardiovascular mor-
tality) in people with MH. A meta-analysis of 7 studies that 
included a total of 11,502 subjects followed over a mean of 

























Figure 3. Scatterplot of systolic and diastolic office blood pressure (BP) for detecting masked hypertension. The + symbol indicates subjects who have 
masked hypertension. The ● symbol indicates subjects who are normotensive. Horizontal and vertical dashed lines indicate the cutoff for which the 
maximum positive likelihood ratio is reached based on systolic office BP and diastolic office BP, respectively.
MH by ABPM  
Yes No Total 
Positive 52 18 70 
Negative 17 13 30 
Office
BP
Total 69 31 100 
A. Using 69% prevalence of MH, 52 (0.75*69) screen true positive and 17 false negative; 13 (0.42*31) screen true 
negative and 18 screen false positive. The positive predictive value in this situation is 74% (52/70)  and the negative 
predictive value is 43% (13/30). 
MH by ABPM  
Yes No Total 
Positive 30 35 65 
Negative 10 25 35 
Office
BP
Total 40 60 100 
B. Using 40% prevalence of MH, 30 (0.75*40) screen true positive and 10 false negative; 25 (0.42*60) screen true 
negative and 35 screen false positive. The positive predictive value in this situation is 46% (30/65) and the negative 
predictive value is 71% (25/35). 
Figure 4. Examples of predictive values using cutoff of 120 mm Hg based on 2 different prevalence rates of masked hypertension (MH). (a) Using 69% 
prevalence of MH, 52 (0.75 × 69) screen true positive and 17 screen false negative; 13 (0.42 × 31) screen true negative and 18 screen false positive. The 
positive predictive value in this situation is 74% (52/70), and the negative predictive value is 43% (13/30). (b) Using 40% prevalence of MH, 30 (0.75 × 40) 
screen true positive and 10 screen false negative; 25 (0.42 × 60) screen true negative and 35 screen false positive. The positive predictive value in this situ-
ation is 46% (30/65), and the negative predictive value is 71% (25/35). Abbreviations: ABPM, ambulatory BP monitoring; BP, blood pressure.
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8  years showed a 2-fold higher incidence of CVD events 
(hazard ratio (HR)  =  2.00; 95% CI  =  1.58–2.52) in people 
with MH compared with those with true normotension.7 
This risk approaches the risk conferred by sustained hyper-
tension (HR = 2.28; 95% CI = 1.87–2.78).
Similar to our findings, other investigators have found that 
people with office BPs in the prehypertension range have a 
high prevalence (i.e., pretest probability) of MH. In a study of 
a community sample of 813 adults with prehypertension, the 
subset with BP in the 120–129/80–84 mm Hg range had a prev-
alence of MH of 27%, and those with BP in the 130–139/85–
89 mm Hg range had a prevalence of MH of 52%.12 Much of 
the elevated CVD risk of office prehypertension is attributable 
to MH.17,18 Such findings suggest that office BP level may be an 
important factor in considering who to test for the presence of 
MH. However, our data indicate that office BP alone may not 
perform efficiently enough to guide these clinical decisions.
One critical question remaining to be answered is whether 
treatment of people identified with MH leads to a reduction in 
CVD morbidity and mortality. To move this area of hyperten-
sion research forward and permit testing to determine whether 
treatment of MH reduces CVD events, efficient strategies for 
identifying people with MH need to be developed. Our study 
suggests that no office BP level alone has an adequate sensitiv-
ity and specificity tradeoff. Therefore, other factors should be 
considered, such as age, sex,19 and race. In addition, measures 
such as stress,20 high pulse rate,19 and smoking21 could poten-
tially be incorporated into a model to better define the group 
for whom testing is warranted. Further research is needed to 
develop and confirm such models using prospective studies.
Our measurements of office BP were taken in a research 
setting as opposed to a clinical setting. Research BPs tend to 
be lower than clinical measurements,22 which may result in 
some participants being classified as having MH as opposed 
to sustained hypertension. However, we repeated the analy-
ses using the eligibility office BP (the most recent BP taken 
in the clinic) and saw little differences. The prevalence of 
MH may be higher in our sample than in a general sample of 
primary care patients. However, although prevalence would 
affect the positive and negative predictive values of a screen-
ing test, it would not affect the actual operating character-
istics (sensitivity and specificity) of the screening test itself.
An office BP level alone may not be sufficiently sensitive 
or specific to be used as a screening test to guide clinical 
decision-making about using ABPM in patients with nonel-
evated office BP. Further research might identify other eas-
ily measured clinical variables that could be incorporated, 
along with office BP, in predictive models to streamline 
diagnostic ABPM use. Additional cost-effectiveness analyses 
comparing strategies for accurately diagnosing ambulatory 
hypertension would also be informative.
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